Federation des caisses Desjardins du Quebec Acquires 17,854 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Federation des caisses Desjardins du Quebec increased its holdings in Bristol Myers Squibb by 14.3% during the first quarter, owning 143,018 shares worth $8.72 million.
• Analysts have mixed ratings on Bristol Myers Squibb, with one strong buy, four buys, fifteen holds, and one sell, leading to a consensus rating of "Hold" and an average price target of $56.38.
• Executive vice president David V. Elkins sold 56,000 shares of Bristol Myers Squibb at an average price of $47.33, reducing his ownership by 25.07% to 167,379 shares.

Federation des caisses Desjardins du Quebec boosted its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 14.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 143,018 shares of the biopharmaceutical company's stock after acquiring an additional 17,854 shares during the period. Federation des caisses Desjardins du Quebec's holdings in Bristol Myers Squibb were worth $8,724,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of BMY. Pinney & Scofield Inc. bought a new position in Bristol Myers Squibb during the fourth quarter valued at $25,000. Park Square Financial Group LLC acquired a new position in Bristol Myers Squibb during the 4th quarter worth $26,000. Global Wealth Strategies & Associates boosted its position in shares of Bristol Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 275 shares during the period. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Bristol Myers Squibb in the first quarter valued at $31,000. Finally, Accent Capital Management LLC acquired a new position in shares of Bristol Myers Squibb in the first quarter valued at approximately $33,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Price Performance

NYSE:BMY traded down $0.46 during mid-day trading on Monday, reaching $46.68. The stock had a trading volume of 9,873,564 shares, compared to its average volume of 13,039,980. Bristol Myers Squibb Company has a one year low of $42.96 and a one year high of $63.33. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The stock has a market capitalization of $95.02 billion, a P/E ratio of 18.82, a P/E/G ratio of 2.41 and a beta of 0.35. The firm has a 50 day moving average price of $47.09 and a two-hundred day moving average price of $50.44.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The company had revenue of $12.27 billion for the quarter, compared to analysts' expectations of $11.32 billion. During the same period in the previous year, the firm earned $2.07 EPS. The firm's revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Thursday, July 3rd were given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.3%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb's payout ratio is currently 100.00%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on BMY shares. Citigroup lowered their price objective on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research report on Friday, August 1st. Daiwa America cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Wall Street Zen cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. Finally, Daiwa Capital Markets cut shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 target price on the stock. in a report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $56.38.

Insider Buying and Selling

In other news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president owned 167,379 shares in the company, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.07% of the stock is owned by corporate insiders.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.